Reversing Aging
to Treat Disease

About Us

At Fountain Therapeutics, we have combined the expertise of leaders in aging research and computation to build a pipeline of therapeutics aimed at reversing cellular aging. Our mission is to decouple aging from disease and significantly extend human health span.

Our AI-driven platform extracts previously hidden cellular features to measure aging with remarkable precision. This has enabled us to generate unprecedented insights into the cellular aging process. We have united science, medicine and engineering to turn these insights and technologies into a powerful drug discovery and development engine for the treatment of age-related diseases.

Aging and Health

Aging is the predominant challenge to our health and quality of life.

Cellular aging shares similar biological pathways with many other physiological processes in our body. This provides us with an opportunity for therapeutic intervention to ameliorate many diseases of aging. At Fountain, we are dedicated to developing the first therapeutics to target and reverse aging processes as a new way to treat the many diseases that aging brings.

Fountain Team

Fountain is comprised of an exceptional team of scientists, engineers, physicians, drug hunters and developers, entrepreneurs and visionaries who see the path to a healthier future. Our team members’ unique experiences and extensive expertise in aging research and medicine are merged to achieve a universal goal of building a new way forward to treat age-related health conditions.

Management

William L. Greene, M.D.

William L. Greene, M.D.

Chief Executive Officer

William L. Greene, M.D.

Chief Executive Officer

Dr. Greene brings to Fountain over 20 years of industry experience as a physician, researcher, entrepreneur, venture investor and operating executive.

Prior to Fountain, as chief executive officer of Iconic Therapeutics, he drove the company’s growth from an academic spin-out to a fully integrated discovery and development organization. This included leading the company’s venture financings, advancing its three development programs, including Phase 1 and Phase 2 clinical trials, and completing two large pharma deals. Prior to Iconic, he was a managing director and member of the Investment Committee at MPM Capital, a leading life science investment firm where he served on the boards of several biotechnology and medical device companies, leading investments from inception to exit. He is the founding chairman of the board and head of the Investment Committee for the Global Health Investment Fund, the largest impact-oriented life science venture capital fund devoted to global health. In addition, he co-founded Pear Therapeutics and was on the Board of Maverick Therapeutics until its sale to Takeda. Dr. Greene began his biotechnology career at Genentech, where he was a member of the core team responsible for the development of Lucentis® and Raptiva® and contributed to clinical strategy, trial design and execution, and regulatory interactions in several therapeutic areas.

Dr. Greene received a bachelor’s degree from Wesleyan University and holds a medical degree from the University of California, San Francisco (UCSF). He completed his scientific and medical training at Massachusetts General Hospital, UCSF and Yale.

View Bio
Thomas Rando

Thomas Rando, M.D., Ph.D.

Co-Founder, Chair of the
Board of Directors

Thomas A. Rando, M.D., Ph.D.

Co-founder and Chair of the Board of Directors

Dr. Rando has more than 20 years of experience in aging research and has published over 150 research articles on stem cell aging and tissue repair.

Dr. Rando is the director of the UCLA Broad Stem Cell Research Center. At UCLA he is a professor in the Departments of Neurology and Molecular, Cell and Developmental Biology. Prior to joining UCLA, Dr. Rando served as the director of the Glenn Center for the Biology of Aging at Stanford University School of Medicine. While at Stanford, he was a professor of neurology and neurological sciences and deputy director of the Stanford Center on Longevity. Dr. Rando also served as chief of the neurology service and director of the Center for Regeneration, Repair, and Restoration (CTR3) at the Veterans Affairs Palo Alto Health Care System (VAPAHCS), where he was previously director or the Rehabilitation Research and Development Center of Excellence/REAP and Geriatric Research, Education and Clinical Center. Dr. Rando is a founding director of the Muscular Dystrophy Association clinic at the Stanford Medical Center.

Dr. Rando has been a pioneer and leader in the use of heterochronic parabiosis to study the role of blood and circulating factors in the biology of aging. In 2005 Dr. Rando published a seminal Nature paper demonstrating that factors in young serum can directly reverse many aspects of cellular and tissue aging. Publications from his lab have over 25,000 citations and he has given more than a hundred keynote lectures over the years at a variety of national and international research conferences and high-profile research and medical institutions. He actively serves as editor and board member of numerous scientific journals, including the Journal of Cell Biology, EMBO Journal, PLoS Biology and Aging Cell.

Dr. Rando is a member of the American Academy of Arts and Sciences and the National Academy of Medicine and a fellow of the American Association for the Advancement of Sciences. Over the course of his career, Dr. Rando has received more than 40 award nominations. He is a former Paul Beeson Physician Faculty Scholar in aging, awarded by the American Federation for Aging Research and a former Ellison Medical Foundation senior scholar in aging. In 2005, he received an NIH Director’s Pioneer Award for his groundbreaking research in stem cell biology. He was also a member of the Advisory Council of the NIH’s National Institute of Aging, and holds board positions at numerous institutions, including Max Planck Institute for Biology of Ageing and the Buck Institute for Age Research.

Dr. Rando serves on the scientific advisory board of several biotechnology and pharmaceutical companies, including NDLX Health Sciences and Novo Biosciences Inc. He previously served on the scientific advisory board of Fate Therapeutics, a $1.2 billion market cap company.

Dr. Rando received a B.A. from Harvard College, and holds an M.D. from Harvard Medical School and a Ph.D. in cell and developmental biology from Harvard University.

View Bio
Joe Rodgers

Joseph Rodgers, Ph.D.

Co-Founder,
Director of Biology

Joseph T. Rodgers, Ph.D.

Co-founder, Director of Biology

Dr. Rodgers has 18 years of experience in aging biology, stem cell and regenerative biology, and intermediary metabolism, and has published extensively in the field.

Dr. Rodgers co-founded Fountain in 2018 when he was an Assistant Professor at The Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the Keck School of Medicine of The University of Southern California. In 2019 he joined Fountain fulltime. Over his career, Dr. Rodgers has authored many high-impact publications in Nature, Nature Medicine, Cell Metabolism, Molecular Cell, and PNAS. His research has been cited over 10,000 times. He has received the American Federation of Aging Research (AFAR) Junior Faculty Award, The Baxter Family Foundation Faculty Fellow Award, and the National Institute on Aging K99 Award for his research on aging and tissue repair.

Dr. Rodgers received a B.S. in chemistry and biology from John Carroll University and holds a Ph.D. in biochemistry, cell and molecular biology from The Johns Hopkins University School of Medicine. He completed postdoctoral fellowships at Stanford University and the Dana-Farber Cancer Institute at Harvard Medical School.

View Bio
Tom Cheung

Tom Cheung, Ph.D.

Co-Founder

Tom Cheung, Ph.D.

Co-founder

Dr. Cheung has more than 15 years of experience in stem cell biology, cell metabolism and aging research.

Dr. Cheung is the S H Ho Associate Professor of Life Science at Hong Kong University of Science and Technology (HKUST). His research aims at increasing the understanding in adult stem cell function in the context of tissue regeneration, disease and aging. He is the director of the HKUST-NanFung Joint Laboratory and the HKUST-BGI Joint Research Center, and the associate director of the HKUST biosciences central research facility. Dr. Cheung was a recipient of the Croucher Innovation Award in 2015 for the study of molecular regulation of stem cell aging. He has authored numerous publications, including multiple publications in Nature, Cell Stem Cell, Molecular Cell and Developmental Cell.

Dr. Cheung holds a Ph.D. in biochemistry for the University of Colorado at Boulder and completed postdoctoral work at Stanford University School of Medicine.

View Bio
“Fountain is taking a unique phenotypic-driven approach for the discovery and development of therapeutics to reverse cellular aging.”
Gordon Ringold, Ph.D.
Gordon Ringold, Ph.D. Advisor – CEO, Quadriga Biosciences, Inc.
“Fountain’s AI technology has the potential to strongly impact our understanding of the aging process and the drug development approach within this field.”
Andrew Trister, M.D., Ph.D.
Andrew Trister, M.D., Ph.D.Advisor – Deputy Director, Bill and Melinda Gates Foundation
“Fountain’s foundational understanding of the science of aging is being translated into therapies to reduce the burden of chronic debilitating diseases.”
Thomas Novak, Ph.D.
Thomas Novak, Ph.D.Advisor – CSO, Autobahn Labs, Inc.
“I love how Fountain brings together cutting-edge research, artificial intelligence and pattern recognition to fight the ravages of aging.”
Frank Eeckman
Frank EeckmanAdvisor – Business Advisor, WaveEdge Capital
“Fountain is defined by our collaborative team and groundbreaking science, which includes a phenotypic screening approach with a 21st century angle.”
Matthew Duncton, Ph.D.
Matthew Duncton, Ph.D.Medicinal Chemist
“What draws me to Fountain are the people and their intrinsic motivation to resolving one of the seminal problems in humanity.”
Vinh Tran
Vinh TranEngineer
“What excites me about working with Fountain Therapeutics is the potential limitless impact of our work with the goal of developing therapeutics for aging-related diseases.”
Lincoln Smith, Ph.D.
Lincoln Smith, Ph.D.Scientist
“I’m drawn to Fountain because of the enormous potential we have to change how we age. Imagine not having to live our later years with the toll that aging takes on our health.”
Jessica Johnson
Jessica JohnsonScientist
“I joined Fountain because I was excited to leverage my expertise in machine learning, information theory, and statistical physics towards reversing cellular aging.”
Ryan Zarcone, Ph.D.
Ryan Zarcone, Ph.D.Data Scientist
“Fountain’s research team has the unique ability to translate cutting-edge technology into better lives for patients. Together, we’re making the future a better place.”
Fernando Martinez, Ph.D.
Fernando Martinez, Ph.D.Senior Scientist
“What excites me the most about Fountain's team is their innovative application of computer vision to better understand the biology of aging-related diseases.”
Raj Bhatnagar, Ph.D.
Raj Bhatnagar, Ph.D. Senior Computational Scientist
“I am fascinated by Fountain’s unique technology that combines artificial intelligence and complex science to fight aging.”
Joshua Chin
Joshua ChinLaboratory & Operations Manager
“I joined Fountain Therapeutics so that I could use my passion for data to help solve age-related diseases.”
Conor Corbin
Conor CorbinData Science Intern
“I joined Fountain not only for its potential to identify therapies to reverse cellular aging, but also for the team's powerful and collaborative scientific approach.”
Anne Pipathsouk, Ph.D. 
Anne Pipathsouk, Ph.D. Scientist
“What led me to Fountain is the team's innovative and multi-disciplinary approach toward addressing age-related disease.”
Jesse Rosen
Jesse RosenCheminformatics Intern
“I was drawn to Fountain's incredibly innovative approach to drug development. By Incorporating deep learning and computer vision into a research pipeline, we aim to lessen the overwhelming burden of age-related disease.”
David Le
David LeScientist
“I am inspired by Fountain's unique and innovative deep learning-based approach to address aging disorders to which I am excited to contribute with my expertise and passion for cell biology.”
Bhagawati Jalnapurkar
Bhagawati JalnapurkarSenior Research Associate
Previous
Next

Our Investors

Nan Fung Life Sciences
khosla ventures

Recent News

Fountain Therapeutics to Present at 2nd Annual LifeSci Partners Private Company Summer Symposium

July 19, 2021 Press Release
Read More →

Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer

April 26, 2021 Press Release
Read More →

Fountain Therapeutics to Present at 2nd Annual LifeSci Partners Private Company Summer Symposium

July 19, 2021 Press Release

Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer

April 26, 2021 Press Release

Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease

February 9, 2021 Article

Biopharma Executive Perspectives on 2021

January 11, 2021 Article

A year in Longevity: science perspectives

December 24, 2020 Article

View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?

December 1, 2020 Article

HQ Move Fuels Fountain’s AI Drug Discovery Machine

October 19, 2020 Article

SMA, NMOSD and Aging – From Few to EveryoneOctober 14, 2020 Radio show

October 14, 2020 Podcast

Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco

September 9, 2020 Press Release

Healthy aging – it’s still all about diet and exercise. For now

August 31, 2020 Article

Intervening in the Aging Process to Treat Age-Associated Diseases with John Dimos Fountain Therapeutics

August 11, 2020 Article

Targeting Diseases of Aging at a Cellular Level

July 16, 2020 Article

Fountain Therapeutics: an AI-based platform to reverse cellular aging

July 15, 2020 Article

Hiring During COVID-19: Business as Usual in the New Normal

July 8, 2020 Article

Biotech Startups Look to Test Employees for Covid-19 in Bid to Get Back to Normal

June 17, 2020 Article

Fountain’s ‘hypothesis-free’ approach to Longevity AI

June 1, 2020 Article

Fountain Therapeutics Closes $6 Million Series A-1 Financing

May 19, 2020 Press Release

Fountain fires up aging drugs platform with new $6M financing

May 19, 2020 Article

Four medical school professors elected to American Academy of Arts and Sciences

April 23, 2020 Article

Join Our Team

We are looking for fellow scientists, engineers and entrepreneurs who share our mission of building a new path forward to improve the length of quality life.

Interested in becoming part of our growing team passionate for innovation, technology and aging research?
Reach out to us: careers@fountaintx.com.

Contact Us

We are here to answer any questions you may have about Fountain including our technology and business objectives. Looking to invest in us or exploring a partnering opportunity? Reach out to us:

Scroll to Top